Skip to main content

Abbott Laboratories



) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.5%. By the end of trading, Abbott Laboratories fell 62 cents (-1%) to $61.37 on average volume. Throughout the day, 5.9 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 7.4 million shares. The stock ranged in price between $61.04-$62.03 after having opened the day at $61.64 as compared to the previous trading day's close of $61.99. Other company's within the Drugs industry that declined today were:

Aoxing Pharmaceutical Company



), down 13.2%,

Galena Biopharma



), down 8.7%,

China Pharma



), down 7.6%, and

Scroll to Continue

TheStreet Recommends

Tekmira Pharmaceuticals Corporation



), down 7.5%.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $97.25 billion and is part of the

health care

sector. The company has a P/E ratio of 19.1, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 10.2% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front,

Rosetta Genomics



), up 51.3%,

Accelr8 Technology Corporation



), up 17.3%,

ImmuCell Corporation



), up 15.3%, and

Biosante Pharmaceuticals



), up 14.3%, were all gainers within the drugs industry with




) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech